Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

DataMeds AI, Inc.

NASDAQ: MEDS · Trade & Services · 10 alerts · CIK 2030763

Share price
$0.6421Close, Nov 16
Market cap
$3.68M
Shares outstanding
5.72MLatest SEC cover page
Sector
Trade & Services
Industry
Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All DataMeds AI, Inc. filings on SEC EDGAR ↗

5:13 PM ET 10-Q
Financial Results

DataMeds AI Q3 2026 Results: Turns Profitable, Net Income $10.6M

DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) reported a net income of $10.5 million for the quarter ended September 30, 2026, primarily driven by a $19.1 million gain on debt extinguishment. However, the company experienced a significant decline in nine-month revenues from $21.7 million in 2025 to $6.0 million in 2026, resulting in a year-to-date net loss of $15.6 million.

Key figure
Net income $10.6M
4:16 PM ET 8-K
Financial Results

DataMeds AI Financial Results

DataMEDS AI reported Q3 2026 revenue of $2.7 million, representing 50% sequential growth driven by its Corexa Pharmacy drug dispensing business. The company achieved a net profit of $2.72 per share and regained full compliance with Nasdaq listing standards during the period. Key strategic developments included the launch of the Health Lives Here mobile app and the acquisition of the Helomics cancer diagnostics laboratory.

Term
Q3 2026

“Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.